<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04935112</url>
  </required_header>
  <id_info>
    <org_study_id>516-011</org_study_id>
    <nct_id>NCT04935112</nct_id>
  </id_info>
  <brief_title>A Study to Explore the Effect of Acid-reducing Agents</brief_title>
  <official_title>A Phase 1 Study of the Effect of Acid-reducing Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirati Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mirati Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1 Study of the Effect of Acid-reducing Agents on the Pharmacokinetics of a Single&#xD;
      Oral Dose of Sitravatinib in Healthy Adult Subjects. The study is a single-center,&#xD;
      open-label, 2-period, 2-treatment, fixed-sequence crossover, parallel-group study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 7, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Actual">August 12, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>2 period crossover</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics - Cmax (sitravatinib)</measure>
    <time_frame>Up to Day 7 after dosing</time_frame>
    <description>Maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - AUCâˆž (sitravatinib)</measure>
    <time_frame>Up to 72 hours after dosing</time_frame>
    <description>Area under the plasma concentration-time curve from time zero extrapolated to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - AUClast (sitravatinib)</measure>
    <time_frame>Up to 72 hours after dosing</time_frame>
    <description>Area under the curve from time zero to the last measured time point</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Up to 9 weeks from screening</time_frame>
    <description>Incidence and severity of AEs</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Healthy Adults</condition>
  <arm_group>
    <arm_group_label>Group 1 Treatment A (sitravatinib only)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: A single oral dose of 100 mg sitravatinib on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1 Treatment B (sitravatinib and pantoprazole)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 2: Oral pantoprazole once daily for 7 days (Days 1 to 7) and a single oral dose of 100 mg sitravatinib on Day 7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 Treatment C (sitravatinib only)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: A single oral dose of 100 mg sitravatinib on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 Treatment D (sitravatinib and famotidine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 2: A single oral dose of 100 mg sitravatinib followed by a single oral dose of famotidine 40 mg approximately 2 hours after sitravatinib dose on Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitravatinib</intervention_name>
    <description>100 mg sitravatinib on Day 1</description>
    <arm_group_label>Group 1 Treatment A (sitravatinib only)</arm_group_label>
    <arm_group_label>Group 1 Treatment B (sitravatinib and pantoprazole)</arm_group_label>
    <arm_group_label>Group 2 Treatment C (sitravatinib only)</arm_group_label>
    <arm_group_label>Group 2 Treatment D (sitravatinib and famotidine)</arm_group_label>
    <other_name>MGCD516</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole</intervention_name>
    <description>40 mg QD on Day 1 to Day 7 of Period 2 in Group 1</description>
    <arm_group_label>Group 1 Treatment B (sitravatinib and pantoprazole)</arm_group_label>
    <other_name>Protonix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famotidine</intervention_name>
    <description>40 mg PO 2 hrs after sitravatinib in Period 2 of Group 2</description>
    <arm_group_label>Group 2 Treatment D (sitravatinib and famotidine)</arm_group_label>
    <other_name>Pepcid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index between 18.0 and 32.0 kg/m2, inclusive.&#xD;
&#xD;
          -  In good health, determined by no clinically significant findings from medical history,&#xD;
             physical examination, 12 lead ECG, vital sign measurements, and clinical laboratory&#xD;
             evaluations at screening and/or check-in, as assessed by the investigator (or&#xD;
             qualified designee).&#xD;
&#xD;
          -  Females of childbearing potential will not be pregnant or lactating and must have a&#xD;
             negative result on an approved pregnancy test at screening and check-in. Females of&#xD;
             childbearing potential must agree to use contraception.&#xD;
&#xD;
          -  Male subjects must agree to use contraception.&#xD;
&#xD;
          -  Able to comprehend and willing to sign an ICF and to abide by the study restrictions.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Significant history of clinical manifestation of any metabolic, allergic,&#xD;
             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,&#xD;
             gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as&#xD;
             determined by the investigator.&#xD;
&#xD;
          -  History of significant hypersensitivity, intolerance, or allergy to any drug compound,&#xD;
             food, any components of the IMP, or other substance (not including seasonal&#xD;
             allergies), unless approved by the investigator.&#xD;
&#xD;
          -  History of intestinal disease, inflammatory bowel disease, major gastric surgery, or&#xD;
             other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption&#xD;
             syndrome) likely to alter absorption of study treatment or result in inability to&#xD;
             swallow oral medications. (Uncomplicated appendectomy and hernia repair are allowed.&#xD;
             Cholecystectomy is not allowed.)&#xD;
&#xD;
          -  History of Gilbert's syndrome or suspicion of Gilbert's syndrome based on elevated&#xD;
             total and indirect bilirubin (may be confirmed by repeat).&#xD;
&#xD;
          -  Use or intend to use any medications/products known to alter drug absorption,&#xD;
             metabolism, or elimination processes, including St. John's wort, within 30 days prior&#xD;
             to study drug administration on Day 1 of Period 1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Curtis Chin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mirati Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit Inc.</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 10, 2021</study_first_submitted>
  <study_first_submitted_qc>June 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantoprazole</mesh_term>
    <mesh_term>Famotidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

